#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

CHEMOTHERAPY IN INVASIVE AND METASTATIC BLADDER CANCER


Authors: J. Katolická
Authors‘ workplace: Onkologicko-chirurgické oddělení FN u svaté Anny, Brno
Published in: Urol List 2011; 9(3): 40-45

Overview

The invasive bladder cancer is an aggressive epithelial tumour. The standard treatment consists of radical cystectomy. Trials of neoajuvant and adjuvant chemotherapy aim at delaying of relapse and improving the chances of curative treatment. Chemotherapy in metastatic bladder cancer patients is based on cisplatin-regimes.

Key words:
invasive bladder cancer, chemotherapy, biological therapy


Sources

1. Vishnu P, Mathew J, Tan WW. Current therapeutic strategies for invasive and metastatic bladder cancer. Onco Targets and Therapy 2011; 4: 97–113.

2. Raghavan D, Shipley WU, Garnick MMB et al. Bio­logy and management of bladder cancer. N Engl J Med 1990; 322(16): 1129–1138.

3. Teramukai S, Nishiyama H, Matsui Y et al. Evaluation for surrogacy of end points by using data from observational studies: tumor downstaging for evaluating neoadjuvant chemotherapy in invasive bladder cancer. Clin Cancer Res 2006; 12(1): 139–143.

4. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy formuscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists. Lancet 1999; 354(9178): 533–540.

5. Sherif A, Rintala E, Mestad O et al. Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer – Nordic cystectomy trial 2. Scand J Urol Nephrol 2002; 36(6): 419–425.

6. Grossman HB, Natale RB, Tangen CM et al. Neoadjuvant chemotherapy plus cystectomycompa­redwithcystectomyaloneforlocallyadvancedbladdercancer. N Engl J Med 2003; 349(9): 859–866.

7. Malstrom PU, Rintala E, Wahlquist R et al. Five-year follow up of prospective trial of radical cystectomy and neoadjuvant chemotherapy: nordic cystectomy trial 1. The Nordic Cooperative Bladder Cancer Study Group. J Urol 1996; 155(6): 1903–1906.

8. Cortesi E. Neoadjuvant treatment for locally advanced bladder cancer: a randomized prospective clinical trial. American Society of Clinical Oncology Annual Meeting. 1995. Philadelphia, PA.

9. Vale CL. Meta-analysis Group MCTU, London, UK. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol 2005; 48(2): 202–205; discussion 205–206.

10. Griffiths G, trialists. OboIco. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastin chemotherapy for muscle-invasive bladder cancer: long term results of the BA06 30894 Trial. J Clin Oncol 2011. doi: 10.1200/JCO.2010. 32.3139

11. Herr HW, Faulkner JR, Grossman HB et al. Surgi­cal factors influence bladder cancer outcomes: a cooperative group report. J Clin Oncol 2004; 22(14): 2781–2789.

12. von der Maase H, Hansen SW, Roberts JT et al. Gemcitabin and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advance dormetastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; 18(17): 3068–3077.

13. Dash A, Pettus JA, Bochner BH et al. Efficacy of neoadjuvant gemcitabine plus cisplatine (GC) in muscle-invasive urothelial cancer (UC). American Society of Clinical Oncology Annual Meeting 2007; Chicago, IL.

14. Smith DC, Grivas P, Daignault S et al. A phase II trial ofneoadjuvant ABI-007, carboplatine and gemcitabine (ACG) in patients with localy advanced carcinoma of bladder. American Society of Clinical Oncology Genitourinary cancer symposium; 2011, Orlando, FL.

15. Blick C, Hall P, Pwint T et al. Accelerated MVAC as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of bladder. American Society of Clinical Oncology Genitourinary cancer symposium; 2011, Orlando, FL.

16. Herr HW, Bajorin DF, Scher HI. Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome. J Clin Oncol 1998; 16(4): 1298–1301.

17. Stenberg CN, Pansadoro V, Calabro F et al. Can patients election for bladder preservation be based on response to chemotherapy? Cancer 2003; 97(7): 1644–1652.

18. Sternberg CN, Yagoda A, Scher HI et al. Metho­trexate, vinblastine, doxorubicin and cisplatin for advanced transitional cell carcinoma of the urothe­lium. Efficacy and patterns of response and relapse. Cancer 1989; 64(12): 2448–2458.

19. Loehrer PJ Sr., Einhorn LH, Elson PJ et al. A randomized comparison of cisplatina loneor in combination with methotrexate, vinblastine and doxorubicin in patients with metastatic urothelial carcinoma: a co­ope­rative group study. J Clin Oncol 1992; 10(7): 1066–1073.

20. Logothetis CJ, Dexeus FH, Finn L et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urotelial tumors. J Clin Oncol1990; 8(6): 1050–1055.

21. Sternberg CN, de Mulder PH, Schornagel JH et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Can­cerprotocol no. 30924. J Clin Oncol 2001; 19(10): 2638–2646.

22. von der Maase H, Hansen SW, Roberts JT et al. Gemcitabine and cisplatine versus methotrexate, vinblastine, doxorubicin and cisplatin in advanced ormetastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; 18(17): 3068–3077.

23. Bellmunt J, von der Maase H, Mead GM et al. Randomized phase III study comparing paclita­xel/cisplatine/gemcitabine (PCG) and gemcita­bine/ /cisplatin (GC) in patients with locally advanced (LA) ormetastatic (M) urothelial cancer without prior systemic therapy. American Society of Clinical Oncology Annual Meeting 2007; Chicago, IL.

24. Bamias A, Aravantinos G, Deliveliotis C et al. Docetaxel and cisplatinwith granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advan­ced urothelial carcinoma: a multicenter, rando­mized phase III study from Helenic Cooperative Oncology Group. J Clin Oncol 2004; 22(2): 220–228.

25. Dreicer R, Manola J, Roth BJ et al. Phase III trial methotrexate, vinblastine, doxorubicin and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of urotelium. Cancer 2004; 100(8): 1639–1645.

26. Hahn NM, Stadler WM, Zon R et al. Mature results from Hoosier Oncology Group GU 04–75 phase II trial ofcisplatin (C), gemcitabine (G) and bevacizumab (B) as first-line chemotherapy for metastatic urothelial carcinoma (UC). American Socienty of Clinical Oncology Annual Meeting:2010. Chicago, IL.

27. Hussain RS, Vaishampayan U, Du W et al. Combi­nation paclitaxel, carboplatin, and gemcitabineisan active treatment for advanced urothelial cancer. J ClinOncol 2001; 19(9): 2527–2533.

28. Bellmunt J, Theodore C, Demkov Z et al. Phase III trial of vinflunine plus best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J ClinOncol 2009; 27(27): 4454–4461.

29. Albers P, Park SI, Niegisch G et al. Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment (German Association of urological Oncology (AUO) trial AB 20/99) Ann Oncol 2011; 22(2): 288–294.

30. Sweeney CJ, Roth BJ, Kabbinavar FF et al. Phase II study of pemetrexedfor second-line treatment of transitional cell cancer of the urothelium. J Clin Oncol 2006; 24(21): 3451–3457.

31. Vale CL, On behalf of Meta-analysis Group MCTU, London, UK. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur Urol 2005; 482(2): 189–199; discussion 199–201.

32. Cognetti F, Ruggeri EM, Felici A et al. Adjuvant­chemotherapy (AC) withcisplatin + gemcitabine (GC) versus chemotherapy (CT) at relapse (CR) in patients (pts) with muscle-invasive bladder cancer (MIBC) submitted to radical cystectomy (RC). An Italian multicenter randomised phase III trial. American Society of Clinical Oncology Annual Meeting; 2008. Chicago, IL.

33. Paz-Ares G, Solsona E, Esteban E et al. Rando­mized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: results of the Spanish oncology Genitourinary Group (SOUGUG) 99/01 study. American Society of Clinical Oncology Annual Meeting; 2010. Chicago, IL.

34. Sherif A, Rintala E, Mestad O et al. Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer – Nordic cystectomy trial 2. Scand J Urol Nephrol 2002; 36(6): 419–425.

35. Malmstrom PU, Rintala E, Wahlqvist R et al. Five-years followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: nor-dic cystectomy trial I. The Nordic Cooperative Bladder Cancer Study Group. J Urol 1996; 155(6): 1903–1906.

36. Cortesi E. Neoadjuvant treatment for locally advanced bladder cancer: a randomized prospective clinical trial. American Society of Clinical Oncology Annual Meeting; 1995, Philadelphia, PA.

37. Swanson DA, Liles A, Zagars GK. Preoperative irradiation and radical cystectomy for stages T2 and T3 squamous cell carcinoma of the bladdder. J Urol 1990; 143(1): 37–40.

38. Lughezzani G, Sun M, Jeldres C et al. Adeno­­carcinoma versus urothelial carcinoma of urinary bladder: comparison between pathologic stage a tra­di­­cal cystectomy and cancer-specific mortality. Urology 2010; 75(2): 376–381.

39. Choong NW, Quevado JF, Kaur JS. Small cell carcinoma of the urinary bladder. The Mayo Clinic experience. Cancer 2005; 103(6): 1172–1178.

Labels
Paediatric urologist Urology
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#